CLDN18 and gastroesophageal junction adenocarcinoma: ASKB589, a humanized IgG1 anti-CLDN18.2, was first studied in a phase I/II trial as monotherapy for pre-treated patients with medium-to-high CLDN18.2-positive advanced solid tumors (Part A) or in combination with CAPOX as first-line treatment for patients with medium-to-high CLDN18.2-positive mG/GEJ adenocarcinoma (Part B) [42,43].